Alzheimer's drug-development pipeline: 2016.

ABSTRACT: BACKGROUND:Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. METHODS:We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. RESULTS:There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying treatments (DMTs). Most DMTs address amyloid-related targets (76%). There are 45 agents in phase II being assessed in 52 clinical trials. Phase II trials include 30 DMTs, with 26 small molecules and 4 immunotherapies. There are 24 agents in the first phase of AD drug development. DISCUSSION:Amyloid is the principal target of late-stage deve

SUBMITTER: Cummings J 

PROVIDER: S-EPMC5651348 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature